Parkinson's Disease
Summary
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra pars compacta. It is characterised by the motor features of bradykinesia, rigidity, and rest tremor, along with numerous non-motor features including constipation, anosmia, sleep disturbance, and later cognitive impairment. Diagnosis is clinical. Treatment is primarily with levodopa (most effective) or dopamine agonists, with surgical options (DBS) for advanced disease. PD progresses over years, and management requires multidisciplinary support.
Key Facts
- Definition: Neurodegenerative disorder due to dopaminergic neuron loss in substantia nigra
- Prevalence: 1-2 per 1,000; increases with age (1% >60 years)
- Diagnosis: Clinical — bradykinesia PLUS tremor or rigidity
- Hallmark Pathology: Lewy bodies (α-synuclein)
- First-Line Treatment: Levodopa (with carbidopa/benserazide)
- Specialist Input: All patients should be referred to a specialist
Clinical Pearls
"Bradykinesia is Essential": You CANNOT diagnose Parkinson's disease without bradykinesia. It must be present along with at least one of: rest tremor or rigidity.
Asymmetry is Typical: PD classically starts unilaterally. Symmetric onset or early bilateral disease should raise suspicion of atypical parkinsonism.
Non-Motor Features Precede Motor: Anosmia, constipation, REM sleep behaviour disorder (RBD), and depression often precede motor symptoms by years — the "prodromal phase."
Why This Matters Clinically
PD is the second most common neurodegenerative disorder after Alzheimer's. Early recognition allows appropriate treatment initiation, improving quality of life. Differentiating PD from atypical parkinsonian syndromes and drug-induced parkinsonism is essential.
Incidence & Prevalence
- Prevalence: 1-2 per 1,000 population; ~1% of those >60 years
- Incidence: 10-20 per 100,000 per year
- Trend: Increasing due to ageing population
- Global Impact: ~6 million people affected worldwide
Demographics
| Factor | Details |
|---|---|
| Age | Mean onset 60-65 years; 5-10% young-onset (<50) |
| Sex | Male:Female 1.5:1 |
| Ethnicity | Higher in Caucasian/European |
| Trend | "Parkinson's Pandemic" — fastest-growing neurological disorder |
Risk Factors
| Risk Factor | Association |
|---|---|
| Age | Strongest risk factor |
| Male sex | 1.5x increased risk |
| Genetics | LRRK2, GBA, SNCA, PARK2 (especially young-onset) |
| Pesticide exposure | Paraquat, rotenone |
| Head injury | Associated in some studies |
| Coffee/Smoking | Protective (epidemiological association) |
Mechanism
Step 1: Dopaminergic Neuron Loss
- Progressive degeneration of dopaminergic neurons in substantia nigra pars compacta
- By symptom onset, ~60-70% of neurons already lost
Step 2: Striatal Dopamine Deficit
- Reduced dopamine in striatum (putamen)
- Imbalance in basal ganglia direct/indirect pathways
- → Motor symptoms
Step 3: α-Synuclein Aggregation
- Lewy bodies: Intracellular inclusions containing α-synuclein
- Lewy neurites: Abnormal processes
- Spread of pathology (Braak staging): Brainstem → midbrain → cortex
Step 4: Non-Motor Systems Affected
- Olfactory (anosmia)
- GI (constipation, via enteric nervous system)
- REM sleep (RBD)
- Autonomic (orthostatic hypotension, bladder)
- Cognitive (dementia, later)
Braak Staging
| Stage | Location | Clinical Correlate |
|---|---|---|
| 1-2 | Olfactory bulb, lower brainstem | Anosmia, constipation, RBD (prodromal) |
| 3-4 | Substantia nigra, midbrain | Motor symptoms |
| 5-6 | Neocortex | Dementia |
Symptoms
Motor (Cardinal Features):
| Feature | Description |
|---|---|
| Bradykinesia | Slowness of movement + decrement in amplitude with repetitive movements |
| Rest Tremor | 4-6 Hz, "pill-rolling"; present at rest, improves with action |
| Rigidity | Lead-pipe rigidity; cogwheeling (tremor superimposed on rigidity) |
| Postural Instability | Late feature; impaired postural reflexes |
Non-Motor (Often Prodromal):
| System | Symptoms |
|---|---|
| Autonomic | Constipation, urinary urgency, orthostatic hypotension, erectile dysfunction, hyperhidrosis |
| Sleep | REM sleep behaviour disorder (RBD), insomnia, daytime sleepiness |
| Neuropsychiatric | Depression, anxiety, apathy, hallucinations, dementia |
| Sensory | Anosmia (loss of smell), pain |
| Other | Fatigue, seborrhoea, small handwriting (micrographia) |
Signs
Red Flags (Suggest Atypical Parkinsonism)
[!CAUTION] Red Flags for Atypical Parkinsonism:
- Early falls (within first year)
- Poor or no response to levodopa
- Symmetric onset
- Early autonomic failure (MSA)
- Early dementia (DLB)
- Vertical gaze palsy (PSP)
- Early bulbar dysfunction
- Rapid progression
- Pyramidal/cerebellar signs
Structured Approach
Observation:
- Facies (hypomimia)
- Tremor at rest
- Posture (flexed)
- Gait (shuffling, reduced arm swing)
Assessment of Cardinal Features:
- Bradykinesia: Finger tapping, hand movements, heel tapping (look for decrement)
- Tremor: Rest tremor (distracted); pill-rolling
- Rigidity: Assess tone (lead-pipe, cogwheeling)
Postural Stability:
- Retropulsion test (pull test) — late feature
Special Tests
| Test | Technique | Significance |
|---|---|---|
| Finger tapping | Repetitive thumb-index finger tapping | Bradykinesia: Decrement in amplitude/speed |
| Hand opening/closing | Rapid movements | Same decrement |
| Heel tapping | Foot tapping on ground | Lower limb bradykinesia |
| Glabellar tap (Myerson sign) | Repeated tapping on glabella | Failure to habituate (not specific) |
| Retropulsion test | Pull back on shoulders | Postural instability (late) |
First-Line
Diagnosis is CLINICAL — based on history and examination.
| Test | Purpose |
|---|---|
| No routine bloods/imaging | Diagnosis is clinical |
| MRI Brain | Exclude other causes (normal in PD; rule out vascular, NPH) |
Specialist Investigations
| Test | When | Findings |
|---|---|---|
| DaTSCAN (SPECT) | Diagnostic uncertainty; differentiate PD from essential tremor/drug-induced | Reduced dopamine transporter uptake (striatum) |
| MRI Brain | Rule out structural causes; atypical features | Normal in PD; may show atrophy in atypical syndromes |
| Olfactory Testing | Supportive (anosmia common in PD) | Reduced smell in PD |
| Autonomic Function Tests | If autonomic features prominent | Abnormal in MSA |
Diagnostic Criteria (MDS Clinical Criteria)
Core Criteria:
- Bradykinesia (ESSENTIAL) PLUS at least one of:
- Rest tremor
- Rigidity
Supportive Criteria:
- Excellent response to dopaminergic therapy
- Levodopa-induced dyskinesias
- Rest tremor of a limb
- Olfactory loss
- Cardiac MIBG scintigraphy: Denervation
Exclusion Criteria:
- Drug-induced parkinsonism
- Atypical features (early falls, poor levodopa response, symmetric onset)
Initial Treatment
| Agent | Dose Example | Notes |
|---|---|---|
| Levodopa + Dopa Decarboxylase Inhibitor | Co-careldopa 100/25mg TDS, titrate | Most effective; first-line for most patients |
| Dopamine Agonist | Ropinirole 0.25mg TDS, titrate; Pramipexole; Rotigotine patch | May delay motor complications; more side effects |
| MAO-B Inhibitor | Rasagiline 1mg OD; Selegiline | Monotherapy for mild disease; adjunct |
Advanced Therapies
Motor Fluctuations (Wearing Off):
- More frequent levodopa dosing
- Add COMT inhibitor (entacapone, opicapone)
- Add MAO-B inhibitor (safinamide, rasagiline)
- Add dopamine agonist
Dyskinesias:
- Reduce individual levodopa doses
- Amantadine (antidyskinetic)
Device-Aided Therapies:
- Deep Brain Stimulation (DBS): STN or GPi; for motor fluctuations/dyskinesias
- Levodopa-Carbidopa Intestinal Gel (LCIG): Continuous infusion via PEG-J
- Apomorphine: SC infusion or rescue pen
Non-Motor Management
| Symptom | Treatment |
|---|---|
| Depression | SSRI, SNRI (avoid TCAs long-term) |
| Psychosis | Reduce dopaminergics; clozapine (first-line), quetiapine |
| Dementia | Rivastigmine (acetylcholinesterase inhibitor) |
| Constipation | Macrogol; fibre; hydration |
| Orthostatic Hypotension | Midodrine; fludrocortisone |
| Insomnia / RBD | Clonazepam; melatonin |
Disease-Related
| Complication | Notes |
|---|---|
| Motor fluctuations | Wearing off, on-off phenomenon |
| Dyskinesias | Peak-dose involuntary movements |
| Falls | Due to postural instability |
| Dementia | 40-80% eventually develop |
| Psychosis | Hallucinations, delusions |
| Aspiration pneumonia | Swallowing dysfunction |
| Depression | Common; undertreated |
Treatment-Related
| Drug | Side Effects |
|---|---|
| Levodopa | Nausea (initially), dyskinesias, motor fluctuations |
| Dopamine agonists | Impulse control disorders (gambling, hypersexuality), daytime somnolence, hallucinations |
| MAO-B inhibitors | Insomnia, nausea |
| Amantadine | Livedo reticularis, ankle oedema, hallucinations |
| DBS | Surgical risks; speech/balance problems |
Natural History
PD is progressive but variable. Most patients have good quality of life for many years with treatment. Motor complications (fluctuations, dyskinesias) typically develop after 5-10 years of levodopa therapy. Dementia and falls become prominent in advanced disease.
Outcomes
| Variable | Outcome |
|---|---|
| Life expectancy | Reduced by ~2-5 years compared to general population |
| Dementia | 40-80% eventually develop |
| Motor fluctuations | 50% by 5 years on levodopa |
| Dyskinesias | 30-50% by 5 years on levodopa |
Prognostic Factors
Better Prognosis:
- Tremor-dominant subtype
- Younger onset
- No cognitive impairment
- Good levodopa response
Poorer Prognosis:
- PIGD (postural instability gait difficulty) subtype
- Older onset
- Early cognitive impairment
- Rapid motor progression
Key Guidelines
-
NICE NG71: Parkinson's Disease in Adults (2017) — Diagnosis, referral, pharmacological and non-pharmacological management.
-
Movement Disorder Society Clinical Diagnostic Criteria (2015) — Gold standard diagnostic criteria.
Landmark Trials
PD MED (2014) — Initial PD treatment
- RCT comparing levodopa vs levodopa-sparing strategies
- Key finding: Levodopa provides best early motor control; no long-term disadvantage
- Clinical Impact: Levodopa accepted as first-line for most patients
EARLYSTIM (2013) — Early DBS
- RCT comparing DBS + medical therapy vs medical therapy alone
- Key finding: DBS improves QoL in patients with early motor complications
- Clinical Impact: Supports earlier DBS referral
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Levodopa | 1a | PD MED, meta-analyses |
| Dopamine agonists | 1a | RCTs |
| MAO-B inhibitors | 1a | RCTs |
| DBS | 1b | EARLYSTIM, RCTs |
| Rivastigmine (dementia) | 1b | EXPRESS trial |
What is Parkinson's Disease?
Parkinson's disease is a condition where certain nerve cells in your brain that produce a chemical called dopamine gradually stop working. Dopamine helps control movement, which is why Parkinson's causes stiffness, slowness, and tremor. It can also affect other things like sleep, mood, and bowel function.
Why does it matter?
Parkinson's is a progressive condition, meaning it gradually gets worse over time. However, with the right treatment and support, most people live well for many years. Medications can significantly improve symptoms.
What are the symptoms?
Main movement symptoms:
- Tremor (shaking) — usually at rest
- Slowness of movement
- Stiffness
- Balance problems (later on)
Other symptoms:
- Loss of smell
- Constipation
- Sleep problems
- Low mood or anxiety
- Memory and thinking changes (later)
How is it treated?
-
Medications: The main treatments replace or mimic dopamine:
- Levodopa (most effective; usually becomes necessary)
- Dopamine agonists
- Other tablets to smooth out responses
-
Therapies: Physiotherapy, speech therapy, occupational therapy
-
Surgery (advanced cases): Deep brain stimulation (DBS) can help control symptoms when medications aren't working well enough
What to expect
- Parkinson's progresses slowly — most people have many good years
- Medications work well at first; can be adjusted over time
- Regular follow-up with your specialist is important
- Multidisciplinary team support (physio, OT, SALT, nurses) helps maintain function
When to seek help
Contact your team or GP if:
- Symptoms are getting significantly worse
- You're having problems with medication timing
- You experience hallucinations or confusion
- Falls are increasing
- Mood is low and affecting daily life
Primary Guidelines
- National Institute for Health and Care Excellence. Parkinson's disease in adults (NG71). 2017. nice.org.uk/guidance/ng71
Key Studies
-
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. PMID: 26474316
-
PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-1205. PMID: 24928805
-
Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications (EARLYSTIM). N Engl J Med. 2013;368(7):610-622. PMID: 23406026
Further Resources
- Parkinson's UK: parkinsons.org.uk
- European Parkinson's Disease Association: epda.eu.com
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.